Late-stage clinical trials indicate that a common arthritis drug may be a promising treatment for a leading cause of hair loss.

It's been about 30 years since a new hair loss drug was approved in the US, and women currently have no approved pills for hair loss.

Humans may have as many as 100,000 to 150,000 individual hairs on our scalps, growing at a rate of roughly 1 centimeter per month.

GLP-1s are netting interest for treating autoimmune diseases, but are considered experimental

Already used to treat type 2 diabetes, the novel medications are showing some early promise in experimental studies at reducing inflammation and treating autoimmune conditions including rheumatoid arthritis and inflammatory bowel conditions. But researchers caution that side effects are still under investigation—rarely the medication has caused lupus, an autoimmune disease.

40% of women will have noticeable hair loss by age 50.

Early research suggests CAR-T therapy might treat scleroderma, reducing skin thickening

Clinical data from a couple patients in 2025 indicated that one experimental CAR-T therapy called rese-cel was able to genetically reprogram T cells to eliminate certain problematic immune B cells that were causing the condition. The therapy reduced skin thickening and allowed the patients to halt using immunosuppressive medications and steroids.

Real-time tracking of individual hair cells has revealed that hairs don't actually get pushed out from the root—instead, hair cells are tugged upward by surrounding tissues that act like tiny motors.

A physician with a rare and deadly disease saved his own life by identifying an existing medication that he repurposed for his condition, and now he's using AI to try to do the same for other patients.

Limb regeneration research may lead to treatments for arthritis

For scientists pursuing the cure for arthritis, the holy grail of discoveries lies in how to regrow healthy cartilage inside human joints. While this feat has so far resisted our best scientific attempts, there are plenty of other human tissues—such as the liver and fingertips—that will successfully regenerate.

Telogen effluvium is a common, temporary type of hair loss that can be triggered by severe stress, illness, or other body changes like childbirth—it pushes as much as 70% of hair into its resting phase, causing hair to fall out.

At a 2026 cancer conference, news that a novel pancreatic cancer drug doubled survival times in clinical trials led to a standing ovation.

Scalp cooling caps may help prevent hair loss during chemotherapy by temporarily reducing blood flow to the scalp, thereby reducing the amount of chemotherapy that reaches hair follicles.

Male pattern baldness is not solely inherited from the maternal side; its causes are still under investigation, but scientists think the genetic component of this type of hair loss involves multiple genes.

Male pattern baldness accounts for more than 95% of hair loss in men and is characterized by thinning hair, hair loss, and a receding hairline.

CAR-T is showing promise for treating lupus—previously thought to be incurable

A small number of lupus patients have remained in complete remission for years after undergoing an experimental CAR-T cell therapy that seems to eliminate enough B cells to fuel a "deep reset" of the immune system. CAR-T therapy is also being used experimentally to treat MS, myositis, and other autoimmune disorders. (Some users may experience a paywall.)

How one autoimmune disease patient is questing for inflammation cures

This article's writer, who has Hashimoto's Disease and characteristic symptoms from her body attacking her thyroid—like exhaustion, hair loss, and brain fog—shares big take-aways from an anti-inflammatory retreat in Italy. The writer suggests that a holistic approach to eating, sleeping, and stress management, are the only sustainable ways to lower inflammation.

In 1909, a top public health official in America wrote in an academic journal that baldness was caused almost exclusively by snug-fitting hats.

A new daily MS pill is seeking regulatory approval in 2026

In clinical trials, Roche's fenebrutinib showed promise treating primary progressive MS and doubling relapse-free time in patients with relapsing MS as compared to existing treatment. But some liver damage and two possible drug-related deaths in the trials may make it difficult for the drug to net approval. (Some users may encounter a paywall.)

When people stopped using GLP-1, they regained two-thirds of the weight back.

Combining two cancer drugs increased the life space of mice by 30%

A study shows trametinib and rapamycin, two drugs used for cancer treatment in humans, increased mouse lifespan when used together. The medications delayed the onset of cancer and reduced chronic inflammation, results that will be explored in future research.

A clinical trial is underway in 2026 to help kidney transplant recipients avoid a lifetime of immunosuppressing drugs

This later-stage clinical trial, in Chicago and Taiwan, evaluates the efficacy and safety of a new cellular therapy that may be swapped in for immunosuppressing drugs among kidney transplant recipients. The study randomizes people to either receive standard immunosuppressants or this cellular therapy and fewer immunosuppressants. It only includes kidney transplant recipients receiving organs from live donors so transplant surgery timing won't hinge on the unpredictable schedule of performing surgery and follow-up care when a donor dies.

Why CAR-T therapy has become one of the main focus areas for autoimmune diseases

The therapy, originally targeting cancer, involves taking a patient's own T cells, genetically reprogramming them to recognize and attack a specific target and then infusing them back into patients. For autoimmune diseases, the therapy instead programs them to target immune cells that are causing problems, restoring immune system tolerance.

A snapshot of progress in cancer treatments

The American Association for Cancer Research's "Snapshot of a Year of Progress" offers an overview of significant advancements in cancer research and treatment over the past year. Take a quick look at the rapid pace of scientific discovery and the translation of research findings into clinical practice. In 2024 alone, health regulators approved 15 new anticancer therapies alone.

Cleopatra purportedly recommended grinding up fly heads and rubbing them on areas experiencing hair loss as a treatment.

More than 200 drug trials for Alzheimer's have failed or been abandoned since 2010

The complexity of Alzheimer's disease, coupled with decades of underfunded research efforts, has left patients with little in the way of effective treatments. In recent years, scientists have synthesized several drugs that studies show can slow the progression of Alzheimer's—though the disease itself remains incurable.

Advanced drugs are closing in on cancer's deadliest mutations

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

MS Drugs reduce inflammation, helping reduce relapses and slow disease progression

Disease-Modifying Drugs calm the body's inflammatory response to help stave off relapses—when new or existing MS symptoms show up for a day or longer. Avoiding smoking, exercising, reducing stress via mindfulness, checking for vitamin D deficiencies, drinking more water and eating well, all can slow disease progression. [The jury's still out on if HRT around the time of menopause may reduce dementia risk](https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00122-9/fulltext) Estrogen can reduce inflammation and support neural growth in the brain, and some research has suggested that beginning hormone replacement therapy around menopause—versus later in life—reduces Alzheimer's disease risk. Still, a recent systematic review concluded that taking HRT didn't affect dementia risk, regardless of when women started taking it, so the science remains unsettled.

New eye implant clinical trial recruiting in 2026

University of Southern California researchers have launched a phase 2b clinical trial of a stem cell implant designed to restore vision in people with advanced dry macular degeneration. Patients will be randomized to receive the stem cell implant or a simulated procedure and placebo implant. This type of larger, second-stage clinical trial is designed to confirm efficacy and dosing and to look for side effects. It's one of the stages that precedes the US Food & Drug Administration approval of a device.

Many patients with psoriasis develop other autoimmune diseases, too

A small study published in 2024 found that nearly three-quarters of patients with psoriasis—a condition in which the body attacks healthy skin cells—also developed autoimmune disorders including thyroid diseases, connective tissue diseases, and more, suggesting such connections between these autoimmune disorders warrant further exploration.

Impressionist painter Pierre-Auguste Renoir suffered from arthritis in the 1800s when there were no treatments, and eventually had such limited hand function that he painted with brushes placed in his mouth.

Researchers are investigating how altering the gut microbiome may influence the development of rheumatoid arthritis, which is an autoimmune disease.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

GLP-1s may lower inflammation, possibly helping to combat cognitive decline

An analysis of existing GLP-1 research, published in April 2025, indicated that GLP-1 drugs reduce inflammation, with numerous health benefits. The work notes that GLP-1s were linked with a statistically significant reduction in dementia in randomized clinical trials.

US FDA recently approved the first new schizophrenia drug in decades

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain. (Some users may experience a paywall.)

Rodent research suggests goose bumps may play a role in hair growth—raising questions about if this knowledge could be used to reactive sympathetic nerves in hair follicles to boost hair growth in people.

Stem cell therapy has shown promise in treating spinal injuries in an early-stage clinical trial.

Scientists using gene therapy recently managed to regenerate retinal cells in the lab—a breakthrough for mammals that could potentially lead to future treatments for human retinal diseases.

As of February 2025, there are more than 150 clinical trials using CRISPR technology

The clinical trials are designed to determine whether experimental CRISPR-related therapies are safe and effective. The majority of trials involve treatments for blood disorders, including beta thalassemia.